The effect of estradiol on COX-2, EP2, and EP4 mRNA expression and the extracellular matrix in the cervix of the hypogonadotrophic, ovariectomized ewe.
There is a degree of cervical relaxation in the ewe at estrus that is regulated by changes in prostaglandin synthesis, prostaglandin receptor expression, and changes in the cervical extracellular matrix. It is likely that these are regulated by changes in periovulatory hormones, particularly estradiol. This study determined the effect of estradiol benzoate on the mRNA expression of cyclooxygenase-2 (COX-2) and the prostaglandin E receptors EP(2) and EP(4), the concentration of cervical hyaluronan, and the proportion of smooth muscle and collagen in the cervix of the hypogonadotrophic ovariectomized ewe (Ovis aries). Ovariectomized hypogonadotrophic ewes were given 100 microg estradiol benzoate, and their cervices were collected 0, 24, and 48 h thereafter to determine the expression of cervical COX-2, EP(2), and EP(4) mRNA by in situ hybridization, the concentration of hyaluronan by ELISA, and the proportion of smooth muscle and collagen by Masson's trichrome staining. Estradiol benzoate increased the mRNA expression of COX-2 and EP(4) within 24h after treatment (P<0.05), whereas EP(2) mRNA, hyaluronan, and the ratio of smooth muscle to collagen did not change within 48 h after treatment. The COX-2, EP(2), and EP(4) mRNA expression were greatest in the smooth muscle layers (P<0.05) and least in the luminal epithelium (P<0.05). In conclusion, we inferred that estradiol regulates cervical COX-2 and EP(4) mRNA expression and may regulate cervical relaxation via the synthesis of prostaglandin E(2) and activation of the PGE(2) receptors EP(2) and EP(4).
Kershaw-Young
C M
CM
Department of Veterinary Clinical Sciences, The Royal Veterinary College, North Mymms, Hatfield, Hertfordshire, United Kingdom. claire.young@usyd.edu.au
Scaramuzzi
R J
RJ
McGowan
M R
MR
Pitsillides
A A
AA
Wheeler-Jones
C P D
CP
Khalid
M
M
D000818:Animals; D002064:Buserelin / Q000008:administration & dosage / Q000494:pharmacology; D002584:Cervix Uteri / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D051546:Cyclooxygenase 2 / Q000235:genetics* / Q000378:metabolism; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D005109:Extracellular Matrix / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D007006:Hypogonadism / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D015918:Infusion Pumps, Implantable; D007273:Injections, Intramuscular; D010052:Ovariectomy; D012333:RNA, Messenger / Q000378:metabolism; D018078:Receptors, Prostaglandin E / Q000235:genetics* / Q000378:metabolism; D058307:Receptors, Prostaglandin E, EP2 Subtype; D058309:Receptors, Prostaglandin E, EP4 Subtype; D012756:Sheep / Q000235:genetics / Q000378:metabolism
D012333:RNA, Messenger; D018078:Receptors, Prostaglandin E; D058307:Receptors, Prostaglandin E, EP2 Subtype; D058309:Receptors, Prostaglandin E, EP4 Subtype; D004958:Estradiol; D051546:Cyclooxygenase 2; D002064:Buserelin